Many proteins necessary for sound transduction have been identified through positional cloning of genes that cause deafness 1-3 . We report here that mutations of LRTOMT are associated with profound nonsyndromic hearing loss at the DFNB63 locus on human chromosome 11q13.3-q13.4. LRTOMT has two alternative reading frames and encodes two different proteins, LRTOMT1 and LRTOMT2, detected by protein blot analyses. LRTOMT2 is a putative methyltransferase. During evolution, new transcripts can arise through partial or complete coalescence of genes 4 . We provide evidence that in the primate lineage LRTOMT evolved from the fusion of two neighboring ancestral genes, which exist as separate genes (Lrrc51 and Tomt) in rodents.
We mapped recessive deafness-associated locus DFNB63 (MIM611451) segregating in eight families to a 2.04-cM interval on human chromosome 11q13. 3-q13.4 (refs. 5-7) . This interval includes FGF3, and mutations of this gene cause a form of syndromic deafness (MIM610706) characterized by microtia, microdontia and inner ear agenesis 8, 9 . Three of the eight families were found to co-segregate recessive mutations of FGF3 with all of the features of this syndrome. We used the meiotic recombinations from the five FGF3 mutationnegative families to refine the linkage interval of DFNB63 to 1.03 Mb ( Supplementary Fig. 1 online) . This interval has 26 annotated and predicted genes (NCBI build 36.1). Using genomic DNA from affected members, we sequenced the protein-coding and noncoding exons and approximately 100 bp flanking each exon of all 26 genes. We identified four pathogenic mutations in an uncharacterized gene, LRRC51, renamed LRTOMT ( Fig. 1a and Table 1 ). Using primers designed to hybridize to LRRC51 exons annotated in build 36.1, we determined the complete exon content of LRTOMT by RT-PCR and 5¢ and 3¢ RACE analyses using adult human liver cDNA ( Supplementary Fig. 2 online). We found a total of ten exons comprising five different alternatively spliced transcripts of LRTOMT that are widely expressed (Fig. 1a,b ). Of note, exons 5, 7 and 8 are included in transcripts encoding two different proteins: LRTOMT1 and LRTOMT2. These exons are predicted to be translated in two alternative reading frames (dual reading frames) and encode either the C terminus of LRTOMT1 or the N terminus of LRTOMT2 ( Fig. 1a and Supplementary Fig. 3 online). When translation of transcript D starts in exon 3 (Fig. 1c) , the encoded protein has two leucine-rich repeats and is named LRTOMT1 ( Fig. 1a and Supplementary Fig. 4 online). Translation beginning in exon 5 (transcript D¢, Fig. 1d ) produces LRTOMT2, which is predicted to have a catechol-O-methyltransferase domain. Depending on the use of an alternative acceptor splice site in exon 8, LRTOMT2 can have a predicted transmembrane helix as well ( Fig. 1a and Supplementary Fig. 5 online) . In silico analyses predict that 7% of alternatively spliced human genes have at least one exon that is translated in different reading frames [10] [11] [12] [13] [14] . However, there are few wellstudied examples of dual reading frame transcripts of genes in higher organisms 13, 15 .
The homozygous mutation (358+4A4C) in hearing-impaired individuals of family TR57 alters the splice donor site of exon 8 of LRTOMT (Fig. 1a , Table 1 and Supplementary Fig. 6 online). RT-PCR analysis of LRTOMT revealed that exon 8 was absent in lymphoblastoid RNA transcripts of affected individuals ( Supplementary  Fig. 6b ). The absence of exon 8 results in a reading frameshift and a premature downstream translation stop codon (A29SfsX54) within the mRNA encoding LRTOMT2. Affected individuals of families FT1A-G, FT2 ( Supplementary Fig. 1 ) and PKDF702 (ref. 6) are homozygous for transition mutations 242G4A (R81Q), 313T4C (W105R) and 328G4A (E110K), respectively ( Fig. 1a , Table 1 and Supplementary Fig. 6 ). All three amino acid substitutions in LRTOMT2 are nonconservative 16 and are predicted to alter the catechol-O-methyltransferase domain of LRTOMT2 (Fig. 1a) , and the wild-type residues are evolutionarily conserved down to fugu ( Supplementary  Fig. 5 ). All four mutations of LRTOMT co-segregate with deafness in these families, carriers have normal hearing, and none of the four mutations was detected in ancestry-matched normal-hearing subjects ( Table 1) .
Catechol-O-methyltransferase (COMT, EC 2.1.1.6) catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (Ado-Met) to a hydroxyl group of catechols 17 . The crystal structure of rat COMT (39% identity and 60% similarity to LRTOMT2 for 212 amino acids) was used to model the catechol-O-methyltransferase domain of human LRTOMT2 for prediction of the effect of the missense mutations on this domain (Fig. 2) . The three mutated residues are in helix 1 (R81Q), helix 2 (W105R) and the loop that follows helix 2 (E110K), and thus not in the hypothetical substrate-binding pockets. However, this loop is predicted to be important for the groove that binds the putative methyl acceptor 17 . The Arg81 and Glu110 residues are predicted to form a salt bridge and hydrogen bonds between helix 1 and the loop, and Trp105 is predicted to make hydrophobic interactions in the core between the helices ( Fig. 2b-d) . These residues may therefore be important for protein stability and could indirectly affect the substratebinding region 17 .
Deafness may be due to the predicted destabilizing effects of all four mutations on the catechol-O-methyltransferase domain of LRTOMT2, but we cannot exclude the possibility that it is due to alterations of LRTOMT1 isoforms D and E. Although two of the mutations are located in the 3¢ UTR of mRNA encoding LRTOMT1 isoforms D and E, and a third is predicted to result in a synonymous substitution (A215A), all three could affect mRNA stability or regulation in ways that are difficult to predict. The splice site mutation is predicted to cause a frameshift mutation in mRNAs for both LRTOMT2 and LRTOMT1 ( 
PKDF537 c Pakistani a Nucleotide changes are numbered according to the first coding ATG (see accession codes). b Ancestry-matched normal-hearing subjects. c In family PKDF537, no pathogenic mutations were found either in the coding region of FGF3, LRTOMT or in 25 evolutionary conserved regions in the introns of LRTOMT, suggesting that the mutation might be in a nonconserved region of an intron, in a distant regulatory element, or in another gene in the DFNB63 interval. Alternatively, the hearing loss segregating in this large family may have been spuriously linked to chromosome 11q13.3 despite a lod score of 6.98.
An animal model of LRTOMT would be valuable in evaluating the pathophysiology of these mutations. However, in rodents, there are two separate genes, designated Lrrc51 and Tomt (Fig. 3a) , which together are orthologous to primate LRTOMT. We were unable to detect fusion transcripts of Lrrc51 with Tomt by either RACE or RT-PCR of cDNAs from brain, heart or liver of mouse and rat using all possible combinations of primers depicted in Figure 3a . LRTOMT fusion transcripts could be readily amplified from human liver and heart cDNAs ( Fig. 1a,b ).
Five different primates express transcripts that include nearly all of the exons of LRTOMT as well as a separate transcript equivalent to rodent Lrrc51 ( Supplementary Fig. 7 online). Inspection of the mouse genome reveals that, in a hypothetical fusion transcript between Lrrc51 and Tomt, if the first translation start codon (ATG in exon 5) were to be used in rodents, an in-frame translation stop codon would be present four codons downstream ( Fig. 1d) . A fusion protein between Lrrc51 and Tomt in rodents is also unlikely because the first exon of Tomt does not have an in-frame consensus splice acceptor site ( Supplementary Fig. 2c ).
Mouse Lrrc51 has six exons and is predicted to encode Lrrc51, a 253 residue protein that has two leucine-rich repeats (Fig. 3a) exons of mouse Tomt are predicted to encode Tomt (258 residues), which has one transmembrane helix and a catechol-O-methyltransferase domain (Fig. 3a ). An amino acid sequence comparison between mouse Lrrc51 and human LRTOMT1 shows 85% identity (93% similarity; Supplementary Fig. 4) . A comparison between mouse Tomt and isoform D¢ (residues 34 to 291) of human LRTOMT2 shows 91% amino acid identity (92% similarity; Supplementary Fig. 5 ). RT-PCR and sequence analyses of cDNAs from mouse embryos and adult tissues showed wide expression of Lrrc51 and Tomt (Fig. 3b) . We next examined embryonic expression of mouse Lrrc51 and Tomt using in situ hybridization. Lrrc51 mRNA was expressed in the developing choroid plexus from embryonic day 12.5 (E12.5) onwards and in the epithelium of the developing airway tract from E14.5 onwards (data not shown), and it was detectable in the postnatal inner ear by RT-PCR (Fig. 3b) . Tomt expression was not detected anywhere in the embryo at E12.5, whereas at E14.5 a specific signal was apparent in the developing inner ear. At E16.5, there was expression in the utricle and saccule (data not shown). Detailed images of the cochlear and vestibular epithelia at E18.5 showed that Tomt was expressed specifically in the region of the sensory cells of the cochlea, utricle, saccule and crista ampullaris ( Fig. 3c-e ).
In protein blot analyses of extracts from P7 mouse cochlea, retina and P40 heart, antisera against Lrrc51 detected two bands (Fig. 4a) . We found similar size proteins for LRTOMT1 in human liver, kidney and spleen (Fig. 4b) . Antisera directed against mouse Tomt detected one major band of approximately 28-30 kDa in the cochlea and heart (Fig. 4c) , similar to the deduced size of 28.8 kDa from the amino acid sequence of mouse Tomt isoform a (Fig. 3a) . With protein from human liver and kidney, antisera to mouse Tomt recognized a 38-kDa LRTOMT2 (Fig. 4d) , which we hypothesize is isoform D¢ (32.2 kDa deduced). Taken together, RT-PCR, RACE and protein blot analyses are consistent with the annotation of mouse Lrrc51 and Tomt as separate genes encoding two different proteins and human LRTOMT as a larger fusion gene with transcripts that are indeed translated in two different reading frames giving rise to LRTOMT1 and LRTOMT2, which have no sequence similarity to one another.
To determine the cellular and subcellular localization of Lrrc51 and Tomt, we carried out immunofluorescence confocal microscopy on mouse inner ear. We detected Lrrc51 immunoreactivity with both antisera PB837-K and PB837-T in the cytoplasm of vestibular hair cells and supporting cells (data not shown) as well as in inner (IHC) and outer hair cells (OHCs) of the organ of Corti (Fig. 5a-c) . In OHCs, immunoreactivity of Lrrc51 was most prominent along the basolateral wall and distributed throughout the cytoplasm. OHCs have a high density of voltage-sensitive prestin motors in their lateral plasma membranes 18, 19 that power somatic electromotility 20 and a complex cortical lattice connected to the plasma membrane by pillars [21] [22] [23] . Lrrc51 may have a special function as a component of the OHC lateral wall.
We detected Tomt in the cytoplasm of IHCs and OHCs and their supporting cells ( Fig. 5d-f ) as well as in vestibular hair cells and their Figure 4 Protein blot analyses of mouse Lrrc51 and Tomt, and human LRTOMT1 and LRTOMT2. (a) Protein blot analyses using antisera to mouse LRRC51 and PB837 (K + T) and protein extracts from 7-d-old (P7) mouse cochlea and retina (50 mg protein/lane) showed two bands of a size somewhat larger than the predicted sizes for Lrrc51 protein isoforms A and B, whereas in P40 heart, the lower molecular weight isoform was detected along with a B16 kDa band that might represent isoform C. (b) In human tissue, PB837 (K + T) detected proteins also of a size somewhat larger than predicted for human LRTOMT1 (isoform A, B and C, Fig. 1a ). (c) Protein blotting of antibody to mouse Tomt (PB840-L) using affinity-purified antisera and mouse cochlear protein extracts (P3; 50 mg/lane) showed one band of about the expected size. In protein extracts from P40 heart, one B28-kDa band of the expected deduced size (28.8 kDa) was detected. (d) Protein blot analysis of protein from human tissues using antibodies to mouse Tomt (PB840 L + R) showed a signal in liver and kidney at B37 kDa, slightly larger than the predicted size of 32.2 kDa for LRTOMT2 (isoform D¢).
supporting cells (data not shown) in adult mouse. In the OHCs of the organ of Corti, Tomt was concentrated under the cuticular plate in a manner similar to Lrrc51. We also observed Tomt immunoreactivity in outer phalangeal (Deiters) cells, in particular along the length of plasma membrane of their phalangeal processes. The homology between LRTOMT2 and COMT and the conservation of the majority of the amino acids that are involved in substrate binding 17, 24 suggest that LRTOMT2 might function as a catechol-O-methyltransferase 25 .
Residual methyltransferase activity in COMT-deficient mice has been hypothesized to be derived from an as-yet-unidentified methyltransferase 26 , which might be Tomt. Identification of LRTOMT, which encodes both a leucine-rich protein and a methyltransferase, opens an exciting new field for genetic and physiological studies of the inner ear.
LRTOMT is the first example, to our knowledge, of a human gene that shows transcription-mediated gene fusion and has dual reading frames, although the latter phenomenon is predicted to be common 10 , and may have implications for understanding hereditary disorders. In some cases, unrecognized alternative reading frames may account for pleiotropy as well as phenotypic variation among alleles of other genes.
The selective pressures and adaptive benefits, if any, that give rise to a fusion gene such as LRTOMT are yet to be determined. Transcription-induced chimerism of two neighboring genes can generate bifunctional, multidomain proteins 10 . An additional benefit may be tight co-expression of functionally related proteins 11 , which might be true for LRTOMT1 and LRTOMT2, as the mouse orthologs, Lrrc51 and Tomt, are both expressed in hair cells. Because Lrrc51 and Tomt are separate transcription units, it will be a challenge to model DFNB63 mutations of LRTOMT in the mouse.
METHODS
Subjects and clinical evaluations. Institutional review boards at the National Center of Excellence in Molecular Biology, Lahore, Pakistan (FWA00001758) and the National Institute on Deafness and other Communication Disorders (NIDCD) and National Institute of Neurological Disorders and Stroke (NINDS) at the US National Institutes of Health (OH-93-N-016) approved this study. We also obtained approval from the ethics committees of the medical faculty of the Karadeniz Technical University in Trabzon, Turkey, the Radboud University Nijmegen in The Netherlands and the University Hospital of Sfax in Tunisia. Written informed consent was obtained from all adult participants and from parents of subjects younger than 18 years of age. The Pakistani, Turkish and Tunisian families and some of the clinical data were previously reported [5] [6] [7] . Unpublished Tunisian families segregating nonsyndromic deafness linked to markers on chromosome 11q13.2-q13.3 are shown in Supplementary Figure 1 .
Several participating family members underwent otoscopic examination, pure-tone audiometry and vestibular function testing as previously described [5] [6] [7] . Magnetic resonance imaging or computed-tomography scan analyses were done to examine inner ear structure of two affected individuals and one normal-hearing individual of Pakistani families segregating recessive mutations of FGF3 or LRTOMT.
Genetic linkage and mutation analysis studies. Protocols for linkage analyses were described previously [5] [6] [7] . All exons and intron-exon boundaries of 26 candidate genes in the refined DFNB63 interval were amplified under standard PCR conditions. Sequences of primers used for the amplification of LRTOMT are given in Supplementary Table 1 online, and sequence analysis was done using an ABI 3730 instrument as described earlier 27, 28 . Control DNAs from 88 to 182 normal-hearing Pakistani, Tunisian or Turkish individuals were used to determine mutant allele frequencies ( Table 1) . cDNA cloning and sequence analysis. We used PCR-ready adult human liver cDNA (Ambion) for cloning full-length isoforms of LRTOMT. We isolated poly(A) + RNA (Poly(A)Pure, Ambion) from postnatal day 1 (P1) to P5 inner ear tissue dissected from 50 C57BL/6J mice and synthesized cDNA using an oligo-dT primer and PowerScript reverse transcriptase (Clontech). We used premade adult mouse brain, heart, liver and rat brain cDNAs and Marathon-Ready cDNAs (Clontech). For chimpanzee, rhesus, baboon and lemur, the isoforms of LRTOMT were evaluated using cDNAs prepared from total RNA isolated from brain tissue obtained from the Southwest National Primate Research Center and the Duke Lemur Center. We also obtained rhesus brain PCR-ready cDNA from CytoMol. All PCR products were subcloned and both strands were fully sequenced. The sequences of primers used to PCR-amplify cDNA for LRTOMT, Lrrc51 and Tomt from human, chimpanzee, rhesus, baboon, lemur and rat tissues are provided in Supplementary Table 2 online.
RT-PCR analysis. We established lymphoblast cell lines by EBV transformation of peripheral-blood cells from deaf Turkish subjects and control individuals. Total RNA from these cells was isolated using the RNeasy Midi Kit (Qiagen). Subsequently, cDNA synthesis was done according to standard procedures using random hexamers. We carried out PCR reactions with gene-specific primers designed from sequences in exons 7 and 10 (Supplementary Table 2 ). To evaluate splicing of exon 8 of LRTOMT, we isolated PCR fragments from agarose gel and verified the sequence. For multiple tissue PCR analyses, we used cDNA panels (Clontech) synthesized using the tissues from humans 19 to 69 years old and from mice 8 to 12 weeks old. RNA from human fetal heart, skeletal muscle, liver and lung was obtained from Clontech. cDNA from human fetal cochlear RNA (16 to 22 weeks gestation) was synthesized as described 28 .
Molecular modeling. The crystal structure of rat COMT was used as a template (see Accession codes section below) to build a model of the catechol-Omethyltransferase domain of the human LRTOMT2 (Fig. 2) . The WHAT IFserver was used for modeling, and energy minimization and analysis were done with Yasara (see URLs section below). For the modeled region (residues 79-290) of LRTOMT2, there is 39% sequence identity with rat COMT. The alignment and a rotating figure of the model is available online (see URLs section below).
Digoxigenin cRNA in situ hybridization. Sense and antisense probes for RNA in situ hybridization correspond to the 3¢ ends of murine Tomt and Lrrc51. We carried out PCR reactions to amplify cDNA on mouse total brain cDNA using primers given in Supplementary Table 2 . Amplimers were cloned in both orientations into pCR2.1 using the TOPO TA Cloning Kit (Invitrogen) and sequenced with T7 and M13 primers. Subsequently, PCR reactions were done with T7 and M13 vector primers using the pCR2.1 constructs as a template. We generated digoxigenin (DIG)-cRNA probes by using these PCR products and carried out in situ hybridizations as described previously 28 . The use of animals approved by the animal experiment committee of Utrecht University.
Antibodies, immunocytochemistry and protein blot analysis. LRRC51 (PB837-K and PB837-T) and TOMT (PB840-L and PB840-R) antisera were raised in rabbit against the following synthetic peptides (Princeton Bio-Molecules): KRMGIKPKKVRAKQD (PB837-K), TGLRPVRHSKSGKSLT (PB837-T), IPRLRAQHQLNRADL (PB840-L) and RPRYYLRDLQLLEAHAL (PB840-R). We affinity-purified antisera using AminoLink columns (Pierce Biotechnology) with beaded agarose to which we coupled the corresponding synthetic peptide used as the immunogen. A fluorescein-conjugated secondary antibody to rabbit IgG was obtained from Amersham Pharmacia Biotech. Specificities of antibodies were determined by protein blot analyses and peptide blocking experiments ( Supplementary Fig. 8 online) . No signal was detected when the primary antibody was preincubated for 2 h at room temperature with an excess of the immunizing peptide. Immunocytochemistry was done as described previously 29 .
For protein blot analyses, we sonicated cochlea, retina and heart from C57BL/6J mice (7 and 40 days old) in ice-cold protease inhibitor cocktail (Calbiochem Biosciences). Protein was extracted by boiling for 5 min in SDS-PAGE sample buffer (0.125M Tris-HCl, 20% glycerol, 4% SDS, 0.005% bromophenol blue). A 50-mg protein sample was separated on a 10% Bis-Tris gel (Invitrogen) and transferred to PVDF membrane (Millipore) for protein blot analyses as described 30 . Novex Sharp protein standard (LC5800, Invitrogen) and Precision Plus Protein Prestained Standards (161-0375, Bio Rad) were used for mouse and human tissue blots, respectively. For animal experiments we obtained approval from the NINDS/NIDCD Animal Care and Use Committee (protocol 1263-06).
